• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫治疗和放疗成功治疗晚期肺腺癌诱导的寡转移和反复寡进展。

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy.

机构信息

Department of Internal Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Inje University Busan Paik Hospital, College of Medicine, Busan, Republic of Korea.

Department of Radiology, Inje University Busan Paik Hospital, College of Medicine, Busan, Republic of Korea.

出版信息

Thorac Cancer. 2022 Jul;13(13):1998-2000. doi: 10.1111/1759-7714.14479. Epub 2022 May 22.

DOI:10.1111/1759-7714.14479
PMID:35599247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9250834/
Abstract

Highly active and durable systemic therapies such as targeted therapy and immunotherapy can convert widespread metastatic disease into oligometastatic status, for which metastasis-directed local intervention can control and potentially prolong survival. Radiation therapy is an effective therapeutic option for oligometastatic and oligoprogressive disease. Here, we present a case of induced oligometastasis and repeated oligoprogressive lung cancer in which more than 6 years of survival was achieved with a combination of immunotherapy and radiotherapy.

摘要

高活性和持久的全身治疗，如靶向治疗和免疫治疗，可以将广泛转移的疾病转化为寡转移状态，对于这种情况，转移灶导向的局部干预可以控制并可能延长生存。放射治疗是寡转移和寡进展性疾病的有效治疗选择。在这里，我们报告了一例诱导性寡转移和反复寡进展性肺癌病例，通过免疫治疗和放射治疗联合治疗，患者实现了超过 6 年的生存。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baa3/9250834/1e57e22ce8d7/TCA-13-1998-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baa3/9250834/1e57e22ce8d7/TCA-13-1998-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baa3/9250834/1e57e22ce8d7/TCA-13-1998-g002.jpg

相似文献

1
Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy.免疫治疗和放疗成功治疗晚期肺腺癌诱导的寡转移和反复寡进展。
Thorac Cancer. 2022 Jul;13(13):1998-2000. doi: 10.1111/1759-7714.14479. Epub 2022 May 22.
2
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.寡转移/寡进展性非小细胞肺癌患者的立体定向放疗和分割立体定向放疗：198 例“根治性”治疗患者的多机构系列研究结果。
Lung Cancer. 2020 Mar;141:1-8. doi: 10.1016/j.lungcan.2019.12.019. Epub 2020 Jan 3.
3
Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma.寡转移肺腺癌局部激进消融放疗可降低进展风险。
Cancer Res Treat. 2024 Jan;56(1):115-124. doi: 10.4143/crt.2023.600. Epub 2023 Aug 29.
4
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.立体定向消融放疗与全身治疗在肺癌颅外寡转移、寡复发、寡残留和寡进展中的应用。
BMC Cancer. 2019 Dec 19;19(1):1237. doi: 10.1186/s12885-019-6449-8.
5
American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.美国镭射医学会寡转移或寡进展性非小细胞肺癌放射治疗适用准则。
Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):361-375. doi: 10.1016/j.ijrobp.2021.09.022. Epub 2021 Sep 25.
6
Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.立体定向放疗治疗寡转移或寡进展妇科恶性肿瘤患者：多机构分析。
Int J Gynecol Cancer. 2020 Jun;30(6):865-872. doi: 10.1136/ijgc-2019-001115. Epub 2020 Apr 8.
7
Role of radiation in oligometastases and oligoprogression in metastatic non-small cell lung cancer: consensus and controversy.辐射在转移性非小细胞肺癌寡转移和寡进展中的作用：共识与争议。
Expert Rev Respir Med. 2023 Jul-Dec;17(11):1033-1040. doi: 10.1080/17476348.2023.2284362. Epub 2023 Dec 26.
8
[Therapeutic options for oligoprogressive non-small cell lung cancer].[寡进展性非小细胞肺癌的治疗选择]
Rev Mal Respir. 2019 Apr;36(4):519-526. doi: 10.1016/j.rmr.2018.04.011. Epub 2019 Apr 19.
9
Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.寡转移非小细胞肺癌：立体定向消融放疗的叙述性综述。
Ann Palliat Med. 2021 May;10(5):5944-5953. doi: 10.21037/apm-20-1409. Epub 2021 Feb 23.
10
Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.优化寡转移和寡进展性非小细胞肺癌的局部治疗以提高生存率。
J Natl Compr Canc Netw. 2022 May;20(5):531-539. doi: 10.6004/jnccn.2021.7117.

引用本文的文献

1
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.晚期肝细胞癌免疫治疗后持久缓解者的结局——以寡进展的局部区域治疗为重点
Liver Cancer. 2024 Feb 1;13(5):509-521. doi: 10.1159/000536549. eCollection 2024 Oct.
2
Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives.寡转移癌：潜在生物标志物、新出现的挑战及新视角
Cancers (Basel). 2023 Mar 17;15(6):1827. doi: 10.3390/cancers15061827.

本文引用的文献

1
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.接受PD-(L)1抑制剂治疗的寡进展性非小细胞肺癌
Cancers (Basel). 2020 Apr 23;12(4):1046. doi: 10.3390/cancers12041046.
2
Integration of radiotherapy and immunotherapy for treatment of oligometastases.放疗与免疫治疗联合治疗寡转移瘤。
Lancet Oncol. 2019 Aug;20(8):e434-e442. doi: 10.1016/S1470-2045(19)30157-3. Epub 2019 Jul 29.
3
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
肺癌免疫疗法与化疗和放疗的联合应用：这会是癌症终结的开端吗？
Ther Adv Med Oncol. 2018 Apr 6;10:1758835918762094. doi: 10.1177/1758835918762094. eCollection 2018.
4
Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer.寡转移非小细胞肺癌患者的管理。
J Oncol Pract. 2018 Jan;14(1):23-31. doi: 10.1200/JOP.2017.026500.
5
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.